UK-based molecular diagnostics division of Novacyt which provides custom quantitative PCR (RT-PCR) assay development services as well as PCR kits and reagents.
developed a COVID-19 diagnostic test and in March, 2020 announced that it had increased manufacturing capacity to support production of 2 million COVID-19 tests per month. Novacyt is seeking FDA, Emergency Use Approval (EUA). A favourable performance assessment by Public Health England (PHE) has been reported. The test is part of the Genesig product line and is a real time PCR (RT-PCR) test that is CE-IVD marked for in vitro diagnostics in Europe.